IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a novel form of vitamin B3, at University of Copenhagen and Aarhus...
Tailwinds' Take: CDXC stock has been weak with a combination of lack of news and forecasted sales not picking up until Q3 weighing on the stock. Summer doldrums will likely be your buying opportunity here. IRVINE, Calif., May 29, 2018 (GLOBE NEWSWIRE)...
Quarterly earnings season is the four times each year in which companies give investors an inside look as to what's going on. They not only reveal their sales and profits, but, typically, they provide guidance (either specifically or in...
Tailwinds' Take: expect a lot more work to be done around Alzheimer's with the help of this leading researcher.  RVINE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today...
Many companies in the Tailwinds (TW) coverage universe reported earnings this last week. Here we discuss each of their results (alphabetically), along with a preview of what we expect going forward. AQMS: from TW's perspective, this quarter is yet one...
Tailwinds' Take: this is not a shocking number, but would have liked them to guide to growth resuming sooner. We had trimmed after the Colorado study and will likely buy it back on weakness. IRVINE, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- ChromaDex...
Tailwinds' Take: Not a surprise that Jaksch moves out of the CEO role as this morphs into a consumer company. Fried is an experienced professional who is capable of driving CDXC into a billion dollar company. IRVINE, Calif., April 23, 2018 (GLOBE...
I had the opportunity to stop by the offices of ChromaDex (CDXC) last week in LA. It was a beautiful day in LA and I was in a good mood. From the Company's side, in attendance were Robert Fried,...
Tailwinds' Take: this study reached easily reached the primary endpoint of demonstrating that Niagen increases NAD+ levels. Importantly, the cardiovascular data shows that it has great potential in helping people with high blood pressure. Further studies are definitely warranted...
Shares of Chromadex are not cheap. When you look at this company relative to sales, the $200+ million market cap sticks out like a green thumb. For a supplement company its valued more like a biotech; you're really betting...